[NICE] Regorafenib for previously treated advanced hepatocellular carcinomaTechnology appraisal guidance [TA555]

NICE| January 2019 | Regorafenib for previously treated advanced hepatocellular carcinoma

Final guidance from NICE which recommends Regorafenib as a possible treatment for advanced hepatocellular carcinoma (liver cancer) for the treatment as a possible treatment for advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib and have:

  • a tumour that can’t be removed by surgery (unresectable)
  • Child–Pugh grade A liver impairment
  • an Eastern Cooperative Oncology Group status of 0 or 1.

Full details at NICE 

NICE Consultation: Lenvatinib for untreated advanced hepatocellular carcinoma

NICE guideline: Brain tumours (primary) and brain metastases in adults

NICE | July 2018|Brain tumours (primary) and brain metastases in adults

NICE have published a guideline, it covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

This guideline includes recommendations on:

For full details see NICE 

NICE Guideline Early and locally advanced breast cancer: diagnosis and management

NHS England strikes deal on new NICE recommended lung cancer immunotherapy drug

NHS England | June 2018 | NHS England strikes deal on new NICE recommended lung cancer immunotherapy drug

NHS England have announced it will make lung cancer drug pembrolizumab available for routine use on the NHS.   Trial results show pembrolizumab  extends life for certain adults with lung cancer for more than a year.

lungs-2803208_1280

According to NHS England Pembrolizumab is the first drug to exceed the new budget impact threshold for new products costing more than £20 million a year. The drug, which is also called Keytruda, would have cost around £84,000 per patient at its full list price. NHS England and MSD have agreed a confidential arrangement for reimbursement which will enable NICE to recommend it be routinely available on the NHS (NHS England).

 

The full announcement is available at NHS England